# A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome

> **NCT02968160** · PHASE4 · TERMINATED · sponsor: **Yuhan Corporation** · enrollment: 55 (actual)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DRUG:** Telmisartan 40mg + Rosuvastatin 20mg
- **DRUG:** Telmisartan 80mg + Rosuvastatin 20mg
- **DRUG:** Telmisartan 40mg, 80 mg
- **DRUG:** Rosuvastatin 20mg

## Key facts

- **NCT ID:** NCT02968160
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 55 (ACTUAL)
- **Why stopped:** Due to poor enrollment rate
- **Last updated:** 2019-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02968160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02968160, "A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02968160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*